Enter to open, tab to navigate, enter to select
Antitrust risk-shifting provisions in Amicus Therapeutics, Inc./Scioderm, Inc. merger agreement
| August 30, 2015 • Antitrust Risk-shifting • $220 million (subject to purchase price adjustment and additional earn-out payment). |
End of Document
© 2024 Thomson Reuters. No claim to original U.S. Government Works.